Sign in

Centre approves Sputnik booster shot, says official

“Details should be firmed-up soon, and the process should also begin at the earliest to ensure that people who have taken Sputnik V will get their booster dose,” said the person quoted above, on the condition of anonymity, adding, that it could be a matter of a few weeks.

Published on: May 7, 2022, 06:37:26 IST
By , Hindustan Times, New Delhi
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

With the Centre giving a go-ahead for Sputnik Light to be used as a booster dose, nearly 650,000 people who took the first dose of Sputnik V will now be able to access the vaccine at private vaccination centres, people familiar with the matter said on Friday.

A medical specialist holds a vial of Sputnik V vaccine against Covid-19.  (REUTERS)
A medical specialist holds a vial of Sputnik V vaccine against Covid-19.  (REUTERS)

“Details should be firmed-up soon, and the process should also begin at the earliest to ensure that people who have taken Sputnik V will get their booster dose,” said the person quoted above, on the condition of anonymity, adding, that it could be a matter of a few weeks.

Pharma company Dr Reddy’s Laboratories, which has the rights for marketing and distribution to the Russian anti-Covid vaccine in India, has started discussions with the manufacturing partners, hospitals, and also with the government to make the option available on the CoWIN platform.

“This week, component 1 of Sputnik V (or Sputnik Light) was approved for administration at private centres as the precaution dose for those who received Sputnik V as their primary vaccine. Having now received official confirmation of the approval, we are working with manufacturing partners in India...,” said Dr Reddy’s statement.

“Last year, the initial doses landed from Russia but for booster doses, Indian manufacturers that Russian Direct Investment Fund (RDIF) has partnered with will be asked to produce the requisite doses. The volume isn’t huge; therefore all might not be asked to manufacture,” said the person, requesting anonymity.

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More